Meag Munich Ergo’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $39.4M | Sell |
1,624,887
-448,907
| -22% | -$10.5M | 1.11% | 41 |
|
|
2025
Q1 | $52.5M | Sell |
2,073,794
-385,034
| -16% | -$10.1M | 1.54% | 26 |
|
|
2024
Q4 | $65M | Buy |
2,458,828
+172,602
| +8% | +$4.68M | 2.05% | 7 |
|
|
2024
Q3 | $66.2M | Buy |
2,286,226
+233,900
| +11% | +$6.82M | 2.08% | 8 |
|
|
2024
Q2 | $57.4M | Hold |
2,052,326
| – | – | 1.91% | 13 |
|
|
2024
Q1 | $57M | Sell |
2,052,326
-27,000
| -1% | -$749K | 2.06% | 13 |
|
|
2023
Q4 | $59.9M | Buy |
2,079,326
+420,082
| +25% | +$12.7M | 2.27% | 6 |
|
|
2023
Q3 | $55M | Buy |
1,659,244
+141,957
| +9% | +$5.02M | 2.4% | 3 |
|
|
2023
Q2 | $55.7M | Buy |
1,517,287
+140,882
| +10% | +$5.48M | 2.42% | 3 |
|
|
2023
Q1 | $56.2M | Buy |
1,376,405
+288,709
| +27% | +$12.5M | 2.66% | 4 |
|
|
2022
Q4 | $55.7M | Sell |
1,087,696
-6,034
| -0.6% | -$289K | 3% | 5 |
|
|
2022
Q3 | $47.9M | Buy |
1,093,730
+144,348
| +15% | +$7.01M | 2.91% | 4 |
|
|
2022
Q2 | $49.8M | Buy |
949,382
+247,702
| +35% | +$12.6M | 2.97% | 3 |
|
|
2022
Q1 | $36.8M | Buy |
701,680
+157,297
| +29% | +$8.16M | 2.66% | 9 |
|
|
2021
Q4 | $31.9M | Buy |
+544,383
| New | +$27M | 2.27% | 14 |
|
|
2021
Q2 | – | Sell |
-25,000
| Closed | -$906K | – | 344 |
|
|
2021
Q1 | $906K | Buy |
+25,000
| New | +$888K | 0.09% | 194 |
|
|
2020
Q4 | – | Sell |
-16,864
| Closed | -$587K | – | 207 |
|
|
2020
Q3 | $587K | Buy |
+16,864
| New | +$591K | 0.11% | 157 |
|
|
2020
Q2 | – | Sell |
-2,214
| Closed | -$69K | – | 229 |
|
|
2020
Q1 | $69K | Sell |
2,214
-115,931
| -98% | -$3.95M | 0.02% | 190 |
|
|
2019
Q4 | $4.36M | Sell |
118,145
-298,165
| -72% | -$10.6M | 0.47% | 52 |
|
|
2019
Q3 | $14.2M | Buy |
416,310
+157,568
| +61% | +$5.73M | 0.73% | 31 |
|
|
2019
Q2 | $10.7M | Buy |
258,742
+27,404
| +12% | +$1.09M | 0.84% | 25 |
|
|
2019
Q1 | $9.28M | Buy |
+231,338
| New | +$9.26M | 0.76% | 29 |
|
|
2018
Q4 | – | Sell |
-473,778
| Closed | -$19.6M | – | 392 |
|
|
2018
Q3 | $19.6M | Buy |
473,778
+127
| +0% | +$4.89K | 1.16% | 8 |
|
|
2018
Q2 | $16.5M | Sell |
473,651
-407,244
| -46% | -$13.9M | 1.02% | 12 |
|
|
2018
Q1 | $29.4M | Buy |
880,895
+172,245
| +24% | +$5.92M | 1.2% | 9 |
|
|
2017
Q4 | $24.6M | Sell |
708,650
-106,169
| -13% | -$3.62M | 0.95% | 14 |
|
|
2017
Q3 | $27.6M | Buy |
814,819
+663,347
| +438% | +$21.3M | 1.13% | 15 |
|
|
2017
Q2 | $4.82M | Sell |
151,472
-108,771
| -42% | -$3.43M | 0.21% | 141 |
|
|
2017
Q1 | $8.45M | Sell |
260,243
-499,492
| -66% | -$15.7M | 0.33% | 108 |
|
|
2016
Q4 | $23.5M | Buy |
759,735
+563,148
| +286% | +$17.2M | 1.1% | 15 |
|
|
2016
Q3 | $6.22M | Sell |
196,587
-461,422
| -70% | -$15.4M | 0.31% | 102 |
|
|
2016
Q2 | $21.9M | Buy |
658,009
+649,577
| +7,704% | +$20.7M | 1.99% | 9 |
|
|
2016
Q1 | $240K | Sell |
8,432
-896,311
| -99% | -$25.6M | 0.01% | 221 |
|
|
2015
Q4 | $28.2M | Sell |
904,743
-2,758
| -0.3% | -$86.8K | 1.41% | 9 |
|
|
2015
Q3 | $27M | Sell |
907,501
-95,428
| -10% | -$3.06M | 1.44% | 9 |
|
|
2015
Q2 | $31.8M | Sell |
1,002,929
-344,924
| -26% | -$11.2M | 1.64% | 10 |
|
|
2015
Q1 | $44.9M | Hold |
1,347,853
| – | – | 2.15% | 4 |
|
|
2014
Q4 | $40.1M | Sell |
1,347,853
-71,265
| -5% | -$2.04M | 1.81% | 5 |
|
|
2014
Q3 | $39.9M | Buy |
1,419,118
+33,588
| +2% | +$943K | 1.84% | 7 |
|
|
2014
Q2 | $39M | Buy |
1,385,530
+703,975
| +103% | +$20.1M | 1.7% | 8 |
|
|
2014
Q1 | $20.7M | Sell |
681,555
-58,671
| -8% | -$1.75M | 1.53% | 14 |
|
|
2013
Q4 | $21.5M | Sell |
740,226
-156,161
| -17% | -$4.54M | 1.27% | 13 |
|
|
2013
Q3 | $24.4M | Buy |
896,387
+347,211
| +63% | +$9.45M | 1.71% | 10 |
|
|
2013
Q2 | $14.7M | Buy |
+549,176
| New | +$15.2M | 1.11% | 28 |
|
Other funds holding PFE
Meag Munich Ergo's PFE Position: Q2 2025 in Review
Meag Munich Ergo reduced its Pfizer (PFE) stake by 22% in Q2 2025, selling an estimated $10.5M and leaving 1,624,887 shares worth $39.4M. The position accounts for 1.11% of the portfolio, ranked #41.
Meag Munich Ergo first reported a position in PFE in Q2 2013 and has held it in 44 quarters since. The position peaked at $66.2M in Q3 2024. 2,809 funds tracked by Wall St. Rank hold PFE as of Q2 2025.
- Meag Munich Ergo held 1,624,887 shares of Pfizer worth $39.4M as of Q2 2025.
- Meag Munich Ergo sold 448,907 Pfizer shares in Q2 2025, an estimated $10.5M.
- Pfizer made up 1.11% of Meag Munich Ergo's portfolio in Q2 2025, its #41 holding.
- Meag Munich Ergo first reported a position in Pfizer in Q2 2013 and has held it in 44 quarters since.
- Meag Munich Ergo's Pfizer position peaked at $66.2M in Q3 2024.
- 2,809 funds tracked by Wall St. Rank held Pfizer as of Q2 2025.
Based on Meag Munich Ergo's 13F filing for Q2 2025, filed 16 Jul 2025.